Lamotrigine versus levetiracetam or zonisamide for focal epilepsy and valproate versus levetiracetam for generalised and unclassified epilepsy: two SANAD II non-inferiority RCTs

Health Technology Assessment

Richard Brown¹  Dan Hindley²  Catrin O Plumpton³  Dyfrig A Hughes³  Catrin Tudur-Smith⁴  Girvan Burnside⁴  Paula R Williamson⁴  Graeme Sills⁵  Gus Baker⁵  Anthony G Marson⁵  Stephen Howell⁶  Silviya Balabanova⁷  Claire Taylor⁷  Rajiv Mohanraj⁸  John Paul Leach⁹  Melissa Maguire^1,10  Philip EM Smith^1,11  Richard Appleton^1,12  Dave Smith^1,13 

[1] Addenbrooke’s Hospital NHS Foundation Trust, Cambridge, UK;Bolton NHS Foundation Trust, Royal Bolton Hospital, Bolton, UK;Centre for Health Economics and Medicines Evaluation, Bangor University, Bangor, UK;Department of Health Data Science, University of Liverpool, Liverpool, UK;Department of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, UK;Department of Neurology, Royal Hallamshire Hospital, Sheffield, UK;Liverpool Clinical Trials Centre, University of Liverpool, Liverpool, UK;Salford Royal NHS Foundation Trust, Manchester, UK;School of Medicine, University of Glasgow, Glasgow, UK;School of Medicine, University of Leeds, Leeds, UK;The Alan Richens Epilepsy Unit, University Hospital of Wales, Cardiff, UK;The Roald Dahl EEG Unit, Alder Hey Children’s Health Park, Liverpool, UK;The Walton Centre NHS Foundation Trust, Liverpool, UK;

关键词: randomised controlled trials;    child;    adult;    humans;    epilepsies, partial;    epilepsy, generalised;    valproic acid;    lamotrigine;    levetiracetam;    zonisamide;    cost–benefit analysis;    technology assessment, biomedical;    intention-to-treat analysis;    quality of life;    quality-adjusted life-years;    united kingdom;   

DOI  :  10.3310/hta25750

来源: DOAJ

【 摘 要 】

Background: Levetiracetam (Keppra®, UCB Pharma Ltd, Slough, UK) and zonisamide (Zonegran®, Eisai Co. Ltd, Tokyo, Japan) are licensed as monotherapy for focal epilepsy, and levetiracetam is increasingly used as a first-line treatment for generalised epilepsy, particularly for women of childbearing age. However, there is uncertainty as to whether or not they should be recommended as first-line treatments owing to a lack of evidence of clinical effectiveness and cost-effectiveness. Objectives: To compare the clinical effectiveness and cost-effectiveness of lamotrigine (Lamictal®, GlaxoSmithKline plc, Brentford, UK) (standard treatment) with levetiracetam and zonisamide (new treatments) for focal epilepsy, and to compare valproate (Epilim®, Sanofi SA, Paris, France) (standard treatment) with levetiracetam (new treatment) for generalised and unclassified epilepsy. Design: Two pragmatic randomised unblinded non-inferiority trials run in parallel. Setting: Outpatient services in NHS hospitals throughout the UK. Participants: Those aged ≥ 5 years with two or more spontaneous seizures that require anti-seizure medication. Interventions: Participants with focal epilepsy were randomised to receive lamotrigine, levetiracetam or zonisamide. Participants with generalised or unclassifiable epilepsy were randomised to receive valproate or levetiracetam. The randomisation method was minimisation using a web-based program. Main outcome measures: The primary outcome was time to 12-month remission from seizures. For this outcome, and all other time-to-event outcomes, we report hazard ratios for the standard treatment compared with the new treatment. For the focal epilepsy trial, the non-inferiority limit (lamotrigine vs. new treatments) was 1.329. For the generalised and unclassified epilepsy trial, the non-inferiority limit (valproate vs. new treatments) was 1.314. Secondary outcomes included time to treatment failure, time to first seizure, time to 24-month remission, adverse reactions, quality of life and cost-effectiveness. Results: Focal epilepsy. A total of 990 participants were recruited, of whom 330 were randomised to receive lamotrigine, 332 were randomised to receive levetiracetam and 328 were randomised to receive zonisamide. Levetiracetam did not meet the criteria for non-inferiority (hazard ratio 1.329) in the primary intention-to-treat analysis of time to 12-month remission (hazard ratio vs. lamotrigine 1.18, 97.5% confidence interval 0.95 to 1.47), but zonisamide did meet the criteria (hazard ratio vs. lamotrigine 1.03, 97.5% confidence interval 0.83 to 1.28). In the per-protocol analysis, lamotrigine was superior to both levetiracetam (hazard ratio 1.32, 95% confidence interval 1.05 to 1.66) and zonisamide (hazard ratio 1.37, 95% confidence interval 1.08 to 1.73). For time to treatment failure, lamotrigine was superior to levetiracetam (hazard ratio 0.60, 95% confidence interval 0.46 to 0.77) and zonisamide (hazard ratio 0.46, 95% confidence interval 0.36 to 0.60). Adverse reactions were reported by 33% of participants starting lamotrigine, 44% starting levetiracetam and 45% starting zonisamide. In the economic analysis, both levetiracetam and zonisamide were more costly and less effective than lamotrigine and were therefore dominated. Generalised and unclassifiable epilepsy. Of 520 patients recruited, 260 were randomised to receive valproate and 260 were randomised to receive to levetiracetam. A total of 397 patients had generalised epilepsy and 123 had unclassified epilepsy. Levetiracetam did not meet the criteria for non-inferiority in the primary intention-to-treat analysis of time to 12-month remission (hazard ratio 1.19, 95% confidence interval 0.96 to 1.47; non-inferiority margin 1.314). In the per-protocol analysis of time to 12-month remission, valproate was superior to levetiracetam (hazard ratio 1.68, 95% confidence interval 1.30 to 2.15). Valproate was superior to levetiracetam for time to treatment failure (hazard ratio 0.65, 95% confidence interval 0.50 to 0.83). Adverse reactions were reported by 37.4% of participants receiving valproate and 41.5% of those receiving levetiracetam. Levetiracetam was both more costly (incremental cost of £104, 95% central range –£587 to £1234) and less effective (incremental quality-adjusted life-year of –0.035, 95% central range –0.137 to 0.032) than valproate, and was therefore dominated. At a cost-effectiveness threshold of £20,000 per quality-adjusted life-year, levetiracetam was associated with a probability of 0.17 of being cost-effective. Limitations: The SANAD II trial was unblinded, which could have biased results by influencing decisions about dosing, treatment failure and the attribution of adverse reactions. Future work: SANAD II data could now be included in an individual participant meta-analysis of similar trials, and future similar trials are required to assess the clinical effectiveness and cost-effectiveness of other new treatments, including lacosamide and perampanel. Conclusions: Focal epilepsy – The SANAD II findings do not support the use of levetiracetam or zonisamide as first-line treatments in focal epilepsy. Generalised and unclassifiable epilepsy – The SANAD II findings do not support the use of levetiracetam as a first-line treatment for newly diagnosed generalised epilepsy. For women of childbearing potential, these results inform discussions about the benefit (lower teratogenicity) and harm (worse seizure outcomes and higher treatment failure rate) of levetiracetam compared with valproate. Trial registration: Current Controlled Trials ISRCTN30294119 and EudraCT 2012-001884-64. Funding: This project was funded by the National Institute for Health Research (NIHR) Health Technology Assessment programme and will be published in full in Health Technology Assessment; Vol. 25, No. 75. See the NIHR Journals Library website for further project information.

【 授权许可】

Unknown